作者
Placide Mbala-Kingebeni, Catherine Pratt, Mbusa Mutafali-Ruffin, Matthias G Pauthner, Faustin Bile, Antoine Nkuba-Ndaye, Allison Black, Eddy Kinganda-Lusamaki, Martin Faye, Amuri Aziza, Moussa M Diagne, Daniel Mukadi, Bailey White, James Hadfield, Karthik Gangavarapu, Nella Bisento, Donatien Kazadi, Bibiche Nsunda, Marceline Akonga, Olivier Tshiani, John Misasi, Aurelie Ploquin, Victor Epaso, Emilia Sana-Paka, Yannick Tutu Tshia N’kasar, Fabrice Mambu, Francois Edidi, Meris Matondo, Junior Bula Bula, Boubacar Diallo, Mory Keita, Marie RD Belizaire, Ibrahima S Fall, Abdoulaye Yam, Sabue Mulangu, Anne W Rimoin, Elias Salfati, Ali Torkamani, Marc A Suchard, Ian Crozier, Lisa Hensley, Andrew Rambaut, Ousmane Faye, Amadou Sall, Nancy J Sullivan, Trevor Bedford, Kristian G Andersen, Michael R Wiley, Steve Ahuka-Mundeke, Jean-Jacques Muyembe Tamfum
发表日期
2021/4/1
期刊
New England Journal of Medicine
卷号
384
期号
13
页码范围
1240-1247
出版商
Massachusetts Medical Society
简介
During the 2018–2020 Ebola virus disease (EVD) outbreak in North Kivu province in the Democratic Republic of Congo, EVD was diagnosed in a patient who had received the recombinant vesicular stomatitis virus–based vaccine expressing a ZEBOV glycoprotein (rVSV-ZEBOV) (Merck). His treatment included an Ebola virus (EBOV)–specific monoclonal antibody (mAb114), and he recovered within 14 days. However, 6 months later, he presented again with severe EVD-like illness and EBOV viremia, and he died. We initiated epidemiologic and genomic investigations that showed that the patient had had a relapse of acute EVD that led to a transmission chain resulting in 91 cases across six health zones over 4 months. (Funded by the Bill and Melinda Gates Foundation and others.)
学术搜索中的文章
P Mbala-Kingebeni, C Pratt, M Mutafali-Ruffin… - New England Journal of Medicine, 2021